CDTX - Cidara Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$177.88
DETAILS
HIGH:
$221.50
LOW:
$150.00
MEDIAN:
$170.00
CONSENSUS:
$177.88
DOWNSIDE:
19.65%
Market Cap:
5.61B
Volume:
2,690,958
Avg Volume:
1,370,674
52 Week Range:
15.22-221.42
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.53
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
38
IPO Date:
2015-04-15
EPS (TTM):
-26.75
P/E Ratio:
-1.01
Revenue (TTM):
1.27M
Total Assets:
214.80M
Total Debt:
3.58M
Cash & Equiv:
189.82M
Rev Growth (5Y):
-42.8%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-106.6%
Debt/Equity:
0.02
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-06 | $-1.43 | $-1.34 | -6.7% | — | — | — |
| 2025-08-07 | $-1.65 | $-1.87 | +11.8% | — | — | — |
| 2025-05-08 | $-1.66 | $-5.45 | +69.5% | — | — | — |
| 2025-03-06 | $-5.38 | $-5.28 | -1.9% | — | $240000 | — |
| 2024-11-07 | $-2.38 | $-5.22 | +54.4% | — | $400000 | — |
| 2024-08-13 | $-2.05 | $-3.94 | +48.0% | $302000 | $4.7M | -93.6% |
| 2024-04-22 | $-0.80 | $-0.20 | -300.0% | $8.5M | $6.3M | +34.3% |
| 2024-03-28 | $-0.19 | $-0.10 | -90.0% | $17.6M | $11.5M | +52.4% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.27M | 23.28M | 64.45M | 49.57M | 12.07M | 20.91M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (169.83M) | (22.93M) | (33.58M) | (42.47M) | (72.11M) | (41.09M) | (59.02M) | (55.73M) | (48.16M) | (32.19M) | (11.89M) | (1.34M) |
| EPS | -26.75 | -5.25 | -9.61 | -16.20 | -36.03 | -26.78 | -45.62 | -63.69 | -66.49 | -46.76 | -290.15 | -83.04 |
| Total Assets | 214.80M | 67.03M | 47.49M | 75.33M | 60.42M | 68.98M | 79.11M | 79.03M | 106.96M | 109.97M | 24.35M | 201,000 |
| Total Debt | 3.58M | 4.88M | 1.21M | 5.06M | 7.96M | 11.72M | 9.93M | 9.87M | 9.79M | 0 | 0 | 1.48M |
| Cash & Equivalents | 189.82M | 35.78M | 32.73M | 62.27M | 35.91M | 50.27M | 74.56M | 75.31M | 104.62M | 107.51M | 22.80M | 185,000 |
| Operating Cash Flow | (176.53M) | (22.43M) | (28.47M) | (25.23M) | (54.41M) | (28.53M) | (56.70M) | (49.91M) | (39.77M) | (25.96M) | (7.71M) | (1.05M) |
| Free Cash Flow | (176.66M) | (22.94M) | (28.59M) | (25.27M) | (54.60M) | (28.57M) | (56.88M) | (50.22M) | (40.17M) | (27.13M) | (8.70M) | (1.05M) |
| FCF per Share | -27.82 | -5.25 | -8.19 | -9.64 | -26.28 | -19.09 | -43.97 | -57.39 | -55.45 | -39.40 | -212.26 | -64.76 |
| Book Value | 163.31M | (8.21M) | (14.44M) | 21.57M | 10.71M | 37.84M | 59.14M | 59.74M | 88.18M | 103.91M | 21.10M | (1.40M) |
| Cash & ST Investments | 189.82M | 35.78M | 32.73M | 62.27M | 35.91M | 50.27M | 74.56M | 75.31M | 104.62M | 107.51M | 22.80M | 185,000 |
| ROC Equity | -1.04 | N/A | N/A | -1.97 | -6.73 | -1.09 | -1.00 | -0.93 | -0.55 | -0.31 | -0.56 | N/A |